翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月20日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前 ...

Core Viewpoint - The company announced a share buyback of 97,200 H-shares at a total cost of HKD 1.9962 million, with individual share prices ranging from HKD 20.38 to HKD 20.70 [1] Group 1 - The total amount spent on the share buyback is HKD 1.9962 million [1] - The number of H-shares repurchased is 97,200 [1] - The price range for the repurchased shares is between HKD 20.38 and HKD 20.70 per share [1]

Group 1 - The company, Zhenxin Biotechnology-B (02509), announced a share buyback plan on November 19, 2025, involving an expenditure of HKD 1.9962 million to repurchase 97,200 H-shares at a price range of HKD 20.38 to HKD 20.70 per share [1]

Core Viewpoint - The company, Qianxin Biotechnology-B (02509.HK), announced a share buyback of 97,000 shares at a cost of HKD 2 million on November 19 [1] Summary by Categories - **Company Actions** - The company executed a buyback of 97,000 shares, indicating a commitment to enhancing shareholder value [1] - The total expenditure for this buyback was HKD 2 million, reflecting the company's financial strategy [1]

公司名稱： 江蘇荃信生物醫藥股份有限公司 FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 呈交日期： 2025年11月19日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 ...

Core Viewpoint - The company, Qianxin Biotech-B (02509.HK), announced a share buyback on November 18, 2023, spending HKD 1 million to repurchase 49,000 shares [1] Summary by Relevant Sections Share Buyback Activity - On November 18, 2023, Qianxin Biotech-B repurchased 49,000 shares for a total cost of HKD 1 million [1] - On November 17, 2023, the company also repurchased 35,000 shares at a cost of HKD 710,000 [1]

Core Viewpoint - The company, 荃信生物-B (02509), announced a share buyback of approximately 49,000 shares at a cost of about HKD 999,400 on November 18, 2025 [1] Group 1 - The total expenditure for the share buyback is approximately HKD 999,400 [1] - The number of shares repurchased is 48,800 [1] - The date of the transaction is set for November 18, 2025 [1]

Core Viewpoint - Company Zhuhai Biotech-B (02509) announced a share buyback plan, spending approximately HKD 999,400 to repurchase 48,800 shares on November 18, 2025 [1] Summary by Category - **Share Buyback Details** - The company will repurchase a total of 48,800 shares [1] - The total expenditure for this buyback is approximately HKD 999,400 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 江蘇荃信生物醫藥股份有限公司 呈交日期： 2025年11月18日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02509 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包 ...

格隆汇11月17日丨荃信生物-B(02509.HK)公告，11月17日耗资71万港元回购3.5万股。 ...